Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients

Show other versions (1)

<p>At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as...

Full description

Bibliographic Details
Main Authors: V. A. Shuvaev, M. S. Fominykh, I. S. Martynkevich, V. Y. Udaleva, N. A. Potikhonova, M. N. Zenina, K. M. Abdulkadyrov
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Onkogematologiâ
Subjects:
chronic myelogenous leukemia
tyrosine kinase inhibitors
imatinib
dasatinib
thrombocythopenia
neutropenia
romiplostim
Online Access:http://oncohematology.abvpress.ru/index.php/ongm/article/view/12

Internet

http://oncohematology.abvpress.ru/index.php/ongm/article/view/12

Similar Items